OCUL - オキュラ―・セラピュ―ティクス (Ocular Therapeutix Inc.)

OCULのニュース

   Ocular Therapeutix™ Announces First Patient Dosed in Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Post-Surgical Ocular Inflammation and Pain in Children  2020/09/10 11:00:00 Business Wire
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has dosed the first patients in a Phase 3 clinical trial of DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg for the treatment of post-surgical ocular inflammation and pain in children following cataract surgery. “We are pleased to announce th
   Ocular Therapeutix Announces Third Medicare Administrative Contractor to Establish New Published Physician Fee Schedule for Administration of Intracanalicular Inserts  2020/09/04 11:00:00 Business Wire
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that National Government Services, Inc. (NGS), one of seven Medicare Administrative Contractors (MACs), became the third MAC to establish a physician fee schedule for procedure code 0356T for the administration of drug-eluting intracanalicular inserts, in
   Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences  2020/09/03 11:00:00 Business Wire
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present and host investor meetings at the following conferences: 2020 Wells Fargo Virtual Healthcare Conference Date: Thursday, September 10, 2020 Analyst-hosted fireside chat: 4:00 PM ET H.C. Wainwright 22nd Annual Global Investment Conferenc
   The Daily Biotech Pulse: Liver Congress Underway, FDA Approves Companion Diagnostic Test For Clovis Cancer Drug, EUA For Abbott's $5, 15-Minute COVID-19 Test  2020/08/27 12:02:06 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) 10X Genomics Inc (NASDAQ: TXG ) Abbott Laboratories (NYSE: ABT ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Fluidigm Corporation (NASDAQ: FLDM ) ( announced emergency use authorization for its saliva-based COVID-19 test) Generation Bio Co (NASDAQ: GBIO ) Inari Medical Inc (NASDAQ: NARI ) Kura Oncology Inc (NASDAQ: KURA ) Lantern Pharma Inc. (NASDAQ: LTRN ) Ocular Therapeutix Inc (NASDAQ: OCUL ) PPD Inc (NASDAQ: PPD ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Revance Therapeutics Inc (NASDAQ: RVNC ) Silk Road Medical Inc (NASDAQ: SILK ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 26) Odonate Therapeutics Inc (NASDAQ: ODT ) Polypid Ltd (NASDAQ: PYPD ) Stocks In Focus FDA Approves Companion Diagnostic Test For Clovis Oncology's Prostate Cancer Drug Clovis Oncology Inc (NASDAQ: CLVS ) said the FDA approved FoundationOne Liquid CDx, Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY )-owned Foundation Medicine's comprehensive liquid biopsy test for all solid tumors with multiple companion diagnostic indications, including for Rubraca tablets.
   Ocular Therapeutix™ Reports Second Quarter 2020 Financial Results and Business Update  2020/08/07 11:15:00 Business Wire
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative the
   Ocular Therapeutix™ Announces First Patient Dosed in Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Post-Surgical Ocular Inflammation and Pain in Children  2020/09/10 11:00:00 Business Wire
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has dosed the first patients in a Phase 3 clinical trial of DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg for the treatment of post-surgical ocular inflammation and pain in children following cataract surgery. “We are pleased to announce th
   Ocular Therapeutix Announces Third Medicare Administrative Contractor to Establish New Published Physician Fee Schedule for Administration of Intracanalicular Inserts  2020/09/04 11:00:00 Business Wire
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that National Government Services, Inc. (NGS), one of seven Medicare Administrative Contractors (MACs), became the third MAC to establish a physician fee schedule for procedure code 0356T for the administration of drug-eluting intracanalicular inserts, in
   Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences  2020/09/03 11:00:00 Business Wire
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present and host investor meetings at the following conferences: 2020 Wells Fargo Virtual Healthcare Conference Date: Thursday, September 10, 2020 Analyst-hosted fireside chat: 4:00 PM ET H.C. Wainwright 22nd Annual Global Investment Conferenc
   The Daily Biotech Pulse: Liver Congress Underway, FDA Approves Companion Diagnostic Test For Clovis Cancer Drug, EUA For Abbott's $5, 15-Minute COVID-19 Test  2020/08/27 12:02:06 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) 10X Genomics Inc (NASDAQ: TXG ) Abbott Laboratories (NYSE: ABT ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Fluidigm Corporation (NASDAQ: FLDM ) ( announced emergency use authorization for its saliva-based COVID-19 test) Generation Bio Co (NASDAQ: GBIO ) Inari Medical Inc (NASDAQ: NARI ) Kura Oncology Inc (NASDAQ: KURA ) Lantern Pharma Inc. (NASDAQ: LTRN ) Ocular Therapeutix Inc (NASDAQ: OCUL ) PPD Inc (NASDAQ: PPD ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Revance Therapeutics Inc (NASDAQ: RVNC ) Silk Road Medical Inc (NASDAQ: SILK ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 26) Odonate Therapeutics Inc (NASDAQ: ODT ) Polypid Ltd (NASDAQ: PYPD ) Stocks In Focus FDA Approves Companion Diagnostic Test For Clovis Oncology's Prostate Cancer Drug Clovis Oncology Inc (NASDAQ: CLVS ) said the FDA approved FoundationOne Liquid CDx, Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY )-owned Foundation Medicine's comprehensive liquid biopsy test for all solid tumors with multiple companion diagnostic indications, including for Rubraca tablets.
   Ocular Therapeutix™ Reports Second Quarter 2020 Financial Results and Business Update  2020/08/07 11:15:00 Business Wire
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative the
   Ocular Therapeutix™ Reports Second Quarter 2020 Financial Results and Business Update  2020/08/07 11:15:00 Business Wire
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative the
   Ocular Therapeutix™ To Report Second Quarter 2020 Financial Results  2020/07/31 11:00:00 Business Wire
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report second quarter ended June 30, 2020 financial results on Friday, August 7, 2020. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at
   Ocular Therapeutix (OCUL) Expected to Beat Earnings Estimates: Should You Buy?  2020/07/29 16:33:04 Yahoo Finance
Ocular Therapeutix (OCUL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results  2020/07/23 12:25:53 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) ABIOMED, Inc. (NASDAQ: ABMD ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) BioLife Solutions Inc (NASDAQ: BLFS ) CALLIDITAS THER/S ADR (NASDAQ: CALT ) Catalent Inc (NYSE: CTLT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunic Inc (NASDAQ: IMUX ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) ( reported forecast-beating second-quarter results) Medpace Holdings Inc (NASDAQ: MEDP ) Novo Nordisk A/S (NYSE: NVO ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Otonomy Inc (NASDAQ: OTIC ) Penumbra Inc (NYSE: PEN ) Qiagen NV (NYSE: QGEN ) Quest Diagnostics Inc (NYSE: DGX ) ResMed Inc. (NYSE: RMD ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 22) Akouos Inc (NASDAQ: AKUS ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Forma Therapeutics Holdings Inc (NASDAQ: FMTX ) Fusion Pharmaceuticals Inc (NASDAQ: FUSN ) Gritstone Oncology Inc (NASDAQ: GRTS ) Nkarta Inc (NASDAQ: NKTX ) RENALYTIX AI ADR (NASDAQ: RNLX ) (went public Friday) Tricida Inc (NASDAQ: TCDA ) Stocks In Focus Midatech Terminates Sale Process, Strategic Review to Continue Midatech Pharma PLC-ADR (NASDAQ: MTP ), a drug delivery technology company, said it has terminated the formal sale process initiated in late April after it failed to receive any proposals from third parties.
   Ocular Therapeutix Announces Second Medicare Administrative Contractor to Establish New Published Physician Fee Schedule for Administration of Intracanalicular Inserts  2020/07/23 11:00:00 Business Wire
BEDFORD, Mass--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that First Coast Service Options, Inc. (First Coast), one of seven Medicare Administrative Contractors (MACs), became the second MAC to establish a physician fee schedule for procedure code 0356T for the administration of drug-eluting intracanalicular inse

calendar